Some clinical studies have shown that some patients can achieve tumor shrinkage or complete disappearance with the use of dalteplumab, so dalteplumab injection has a certain effect on the treatment of multiple myeloma, but the efficacy of the treatment depends on the condition of the disease, the individual sensitivity to the drug and other factors, there are individual differences. Daltoyumab Daltoyumab is a humanized, anti-CD38 IgG1 monoclonal antibody, which binds to CD38 expressed by tumor cells and induces apoptosis of tumor cells through various immune-related mechanisms such as complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis. For the monotherapy treatment of adult patients with relapsed and refractory multiple myeloma, including patients who have previously received a proteasome inhibitor and an immunomodulator and who experienced disease progression at the time of last therapy. Daltolizumab Injection inhibits the growth of tumor cells and may reduce myeloid-derived suppressor cell, regulatory T-cell and B-cell levels. It is used for the treatment of multiple myeloma in adults who are not candidates for autologous stem cell transplantation; multiple myeloma who have received at least first-line drug therapy; and monotherapy for relapsed or refractory multiple myeloma. The most common adverse reactions include upper respiratory tract infection, neutropenia, thrombocytopenia, infusion-related reactions, diarrhea, nausea, constipation, anemia, peripheral sensory neuropathy, peripheral edema, cough, fever, fatigue, infectious pneumonitis, and fever. The use of this product should be standardized under the guidance of a doctor, and the drug is contraindicated for those who have hypersensitivity reactions to the product.